11 unchanged sentences
Purchased Under
−Removed: January 1, 2024 - January 31, 2024 994 (1)
+Added: April 1, 2024 - April 30, 2024 986 (1)
— $3,849,610,303
−Removed: February 1, 2024 - February 28, 2024 845 (1)
+Added: May 1, 2024 - May 31, 2024 1,058 (1)
— $3,849,610,303
−Removed: March 1, 2024 - March 31, 2024 5,317,518 (1)
+Added: June 1, 2024 - June 30, 2024 1,081 (1)
— $3,849,610,303
1 unchanged sentence
— $3,849,610,303
−Removed: In addition to AbbVie shares repurchased on the open market under a publicly announced program, if any, these shares also included the shares purchased on the open market for the benefit of participants in the AbbVie Employee Stock Purchase Plan – 994 in January;
−Removed: 845 in February;
−Removed: and 862 in March.
+Added: In addition to AbbVie shares repurchased on the open market under a publicly announced program, if any, these shares also included the shares purchased on the open market for the benefit of participants in the AbbVie Employee Stock Purchase Plan – 986 in April;
+Added: 1,058 in May;
+Added: and 1,081 in June.
These shares do not include the shares surrendered to AbbVie to satisfy minimum tax withholding obligations in connection with the vesting or exercise of stock-based awards.
−Removed: 2024 Form 10-Q |
(c) Director and Officer Trading Arrangements
−Removed: During the three months ended March 31, 2024, no director or officer of the company adopted, modified or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408(a) of Regulation S-K, except as provided below.
−Removed: Name & Title Action Taken Date Adopted Type of Trading Arrangement (1)
−Removed: Aggregate Number of Shares to be Sold Pursuant to Trading Arrangement
−Removed: Duration of Trading Arrangement (2)
−Removed: Chairman of the Board
−Removed: and Chief Executive Officer
−Removed: Adoption 03/26/2024 Rule 10b5-1 Trading Arrangement Up to 282,845 Shares Issuable Upon the Exercise of Options
−Removed: Except as indicated by footnote, each trading arrangement marked as a "Rule 10b5-1 Trading Arrangement" is intended to satisfy the affirmative defense of Rule 10b5-1(c), as amended.
−Removed: Except as indicated by footnote, each trading arrangement permitted or permits transactions through and including the earlier to occur of (a) the completion of all sales or (b) the date listed in the table.
−Removed: Each trading arrangement marked as a “Rule 10b5-1 Trading Arrangement” only permitted or only permits transactions upon expiration of the applicable mandatory cooling-off period under the Rule.
+Added: During the three months ended June 30, 2024, no director or officer of the company adopted, modified or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408(a) of Regulation S-K.
2024 Form 10-Q |
1 unchanged sentence
Exhibit Description
−Removed: Form of AbbVie Inc.
−Removed: Performance-Vested Restricted Stock Unit Agreement*
−Removed: Form of AbbVie Inc.
−Removed: Performance Share Award Agreement*
−Removed: Form of AbbVie Inc.
−Removed: Non-Employee Director RSU Agreement (US)*
−Removed: Form of AbbVie Inc.
−Removed: Non-Qualified Stock Option Agreement*
−Removed: Form of AbbVie Inc.
−Removed: Retention RSU Agreement - Ratable Vesting*
Certification of Chief Executive Officer Required by Rule 13a-14(a) (17 CFR 240.13a-14(a)).
5 unchanged sentences
101 The following financial statements and notes from the AbbVie Inc.
−Removed: Quarterly Report on Form 10-Q for the quarter ended March 31, 2024, filed on May 3, 2024, formatted in iXBRL (Inline eXtensible Business Reporting Language):
+Added: Quarterly Report on Form 10-Q for the quarter ended June 30, 2024, filed on August 7, 2024, formatted in iXBRL (Inline eXtensible Business Reporting Language):
(i) Condensed Consolidated Statements of Earnings;
7 unchanged sentences
_______________________________________________________________________________
−Removed: * Denotes management contract or compensatory plan or arrangement required to be filed as an exhibit hereto.
2024 Form 10-Q |
2 unchanged sentences
Chief Financial Officer (Principal Financial Officer)
+Added: August 7, 2024
2024 Form 10-Q |
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.